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ugano, Switzerland; and Maastricht, the Netherlands
ardiac resynchronization therapy (CRT) by biventricular
acing has been established as a nonpharmacologic therapy
or patients with drug-refractory heart failure and ventric-
lar conduction delay (1). A good proportion of patients
reated with CRT show significant amelioration of their
ymptoms and functional capacity, reversal of the maladap-
ive remodeling process, and prolongation in life expectancy.
he proportion of nonresponders (estimated at about 40%)
s likely to be reduced by better selection (such as the
resence and magnitude of mechanical dyssynchrony and
car burden), optimization of therapy application (tuning of
trioventricular and interventricular delay), and choosing
See page 1455
he best pacing site. The most common left ventricular (LV)
acing site selected for delivering CRT is the free lateral
all, but the question is whether adding more pacing sites
ould improve outcome. Indeed, it seems feasible that
lacement of multiple pacing leads at different ventricular
ites would create multiple waves of electrical activation,
hus further reducing asynchrony in case of ventricular
onduction delay. A few recent observational studies in
eart failure patients have attempted simultaneous pacing at
sites within the same LV region, a few case reports
ppeared about pacing at 2 different sites within the LV,
nd some studies have evaluated 2 simultaneous pacing sites
ithin the right ventricle (RV) along with 1 LV pacing site.
lthough the results of these small, single-center, observational
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cientific, and EBR System Inc.tudies showed a large individual variability, triple ventricular
acing sites, no matter whether RV or LV, resulted in a larger
emodynamic improvement compared with conventional
iventricular pacing.
The TRIP-HF (Triple Resynchronization In Paced
eart Failure Patients) study presented in this issue of the
ournal (2) is the first randomized, prospective multicenter
rial comparing a triple-site stimulation—2 epicardial trans-
enous leads placed on the anterior and lateral or postero-
ateral LV wall and 1 RV lead—with conventional biven-
ricular pacing. The TRIP-HF study enrolled a highly
elected yet small group of patients with severe heart failure
resenting with a slow ventricular rate during atrial fibril-
ation (AF). Leclercq et al. (2) showed that compared with
ual-site biventricular pacing, triple-site ventricular stimu-
ation promoted further LV reverse remodeling as assessed
y LV end-systolic and -diastolic volumes and ejection
raction, at 3-month follow-up. The results of this study are
f great interest, and the investigators should be congratu-
ated for having tested this important pathophysiological
oncept. However, there are a few more considerations and
ome caveats that should be considered before widely
pplying triple-site stimulation in larger groups of patients.
The primary echocardiographic objective of the study, the
uality of ventricular resynchronization, as defined as the
ratio, was missed. The Z ratio is calculated simply from
he duration of the ejection and filling times with respect to
he overall cardiac cycle and is an index of global mechanical
yssynchrony in heart failure patients (3). It is one of the
any echocardiographic indexes recently proposed for eval-
ating mechanical dyssynchrony (4). In the TRIP-HF study,
he Z ratio was unchanged after CRT compared with baseline;
oreover, the Z ratio did not significantly change between
he 2 different stimulation modes. Although these results
ay seem paradoxical in light of publications on the
elevance of mechanical dyssynchrony (4), recent publica-
ions from prospective multicenter trials show that several
chocardiographic indexes of mechanical dyssynchrony do
ot predict response to CRT or even change after CRT
5,6). Thus, the results of the TRIP-HF study are not
urprising and support the idea that broad applicability of a
ingle echocardiographic parameter in daily practice is still
ot feasible.
The main secondary end point of the TRIP-HF study was
change in LV end-systolic volume during dual- and
riple-site stimulation. Both end-systolic and -diastolic vol-
mes were reduced more during triple-site stimulation
ompared with dual-site stimulation. As a result, the mean
V ejection fraction increased more during triple-site (9
ercentage points) than during dual-site stimulation (3
ercentage points) compared with baseline. The absolute
ean increase of the LV ejection fraction during dual-site
timulation was unusually modest for this group of patients.
ndeed, patients with AF included in other CRT studies
sing conventional biventricular pacing had similar mean
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Editorial Comment April 15, 2008:1463–5aseline volumes and LV ejection fraction, but at compa-
able follow-up times showed an increase of LV ejection
raction ranging between 6 and 12 percentage points
7–9). An explanation for these and other results may reside
n the inclusion criteria of the TRIP-HF study. After all,
0% of the study population consisted of patients with RV
acing, whereas the other 50% had a de novo implant and
as without the requirement of a wide QRS complex.
ndeed, QRS duration varied widely (SD 47 ms at a mean
alue of 167 ms), implying that several patients with initially
arrow QRS complexes were also included. In such pa-
ients, conventional biventricular pacing may actually not
mprove LV function (6), or even worse, cardiac mechanics
10). Furthermore, although a 3-month run-in period was
sed, in de novo implanted patients some of the effects may
ave been caused by rate regularization. In patients with
oor cardiac function rate regularization, even using RV
acing has beneficial effect in patients with AF and His
undle ablation (11). Therefore, although the study ad-
ressed better application of CRT, the other prerequisite for
he largest beneficial effect of CRT (patient selection) might
ave been less carefully handled. The fact that the
RIP-HF study was performed in patients with a slow
entricular rate during AF in need of antibradycardia pacing
mplies that the benefits of triple-ventricular stimulation can
e related to better ventricular resynchronization without
eing possibly confounded by changes in atrioventricular
ynchronization. However, the benefit of triple-ventricular
timulation clearly needs confirmation in the most common
roup of patients for CRT, that is, sinus rhythm and
entricular conduction disturbance.
The results of the TRIP-HF study also raise pathophys-
ological questions: can addition of a third (anterior) lead
mprove synchrony of activation and contraction? Detailed
lectrical activation mapping studies have shown that the
nterior wall is activated early during intrinsic rhythm in
eart failure patients with LBBB (12), thus one would not
elect this as the single LV pacing site. Indeed, the number
f nonresponders was shown to be higher using anterior
han posterolateral LV lead placement (13). In addition,
nimal studies showed that no additional improvement can
e expected when adding more LV pacing sites to a
ell-chosen one (14). The finding that adding anterior LV
acing to posterolateral wall stimulation seems to improve
RT is therefore not trivial and deserves further exper-
mental and clinical investigation. One possible explana-
ion for the beneficial effect observed during triple pacing
s the technical approach used by the investigators, that
s, the second LV lead was connected to the atrial port
nd was stimulated 25 ms before the RV and the first LV
ead. Consequently, in the triple-site stimulation mode,
RT is not truly simultaneous but is sequential with
oderate LV pre-excitation. It is known from both
nimal studies and patient research that on average, LV
re-excitation provides a better effect than simultaneous
iventricular pacing. Thus, part of the benefit of theriple-site pacing in the TRIP-HF study might be
xplained by the sequential ventricular pacing.
Instead of adding more pacing sites, also attempting to
osition pacing leads to the LV endocardium may improve
RT. Even with larger numbers of epicardial pacing elec-
rodes, the transmural gradient of activation is opposite of the
hysiological one. Endocardial LV pacing may avoid such a
ransmural activation abnormality. Endocardial LV pacing in
eart failure is feasible using a trans-septal approach (15), and
reliminary data show that it is superior to LV epicardial
acing (16). Upcoming technologies such as leadless pacing
ight enable a wider application of LV endocardial pacing.
In conclusion, the TRIP-HF study has delivered several
mportant messages, but confirmation of the results in more
ommon CRT populations and differentiating among pa-
ient categories, as well as comparison with other modalities
or delivering multiple pacing sites, is mandatory. In addi-
ion, the technical challenges and the long-term safety issue
elated to the implantation of 2 transvenous LV leads
hould be remembered.
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